Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[18F]fluorodeoxyglucose-PET in Therapeutic Decision-Making and Theranostics of Breast Cancer.

Created on 11 Nov 2026

Authors

Parth Baberwal, Kapish Jain, Rakesh Kumar

Published in

PET clinics. Nov 10, 2026. Epub Nov 10, 2026.

Abstract

[18F]fluorodeoxyglucose (FDG)-PET/CT informs decisions at almost every point in breast cancer care. It establishes the extent of disease at diagnosis and so determines whether treatment is delivered with curative or palliative intent. This review examines the biology that underlies FDG uptake and explains why uptake varies so markedly between molecular subtypes. It also sets out the evidence supporting FDG-PET/CT in staging and in therapeutic decision-making across chemotherapy, endocrine therapy, HER2-directed treatment, immunotherapy, and radiotherapy planning, before turning to the complimentary role of 18F-FDG PET/CT with theranostic agents.

PMID:
43009437
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement